# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Raymond James analyst Elliot Wilbur maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Outperform and raises the price targe...
HC Wainwright & Co. analyst Oren Livnat reiterates ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and maintains $94 price ...
Truist Securities analyst Gregory Fraser downgrades ANI Pharmaceuticals (NASDAQ:ANIP) from Buy to Hold and lowers the price ...
Alimera Has Filed Lawsuit in the Delaware Court of Chancery to Compel ANI to Close Merger Transaction and Honor its Contractual...